These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23871733)

  • 21. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand binding induces a conformational change in epidermal growth factor receptor dimers.
    Walker F; Rothacker J; Henderson C; Nice EC; Catimel B; Zhang HH; Scott AM; Bailey MF; Orchard SG; Adams TE; Liu Z; Garrett TP; Clayton AH; Burgess AW
    Growth Factors; 2012 Dec; 30(6):394-409. PubMed ID: 23163584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-epidermal growth factor receptor monoclonal antibodies affecting signal transduction.
    Reins HA; Steinhilber G; Freiberg B; Anderer FA
    J Cell Biochem; 1993 Feb; 51(2):236-48. PubMed ID: 8382707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
    Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
    Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.
    Darmoul D; Gratio V; Devaud H; Peiretti F; Laburthe M
    Mol Cancer Res; 2004 Sep; 2(9):514-22. PubMed ID: 15383630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.
    Olszewska W; Obeid OE; Steward MW
    Virology; 2000 Jun; 272(1):98-105. PubMed ID: 10873752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
    Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
    Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Design and activity analysis of chimeric epidermal growth factor fusion vaccine E5T-mSEA].
    Yin Q; Jia H; Zhang Y; Liu C; Ma Q; Zhang B; Zhong H; Xu Q
    Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):357-62. PubMed ID: 20518349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel monoclonal antibodies recognizing the active conformation of epidermal growth factor receptor.
    Ise N; Omi K; Miwa K; Honda H; Higashiyama S; Goishi K
    Biochem Biophys Res Commun; 2010 Apr; 394(3):685-90. PubMed ID: 20226763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.
    Chao G; Cochran JR; Wittrup KD
    J Mol Biol; 2004 Sep; 342(2):539-50. PubMed ID: 15327953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
    Mishra G; Panwar P; Mishra AK
    Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor.
    Baradaran B; Majidi J; Farajnia S; Barar J; Omidi Y
    Hum Antibodies; 2014; 23(1-2):13-20. PubMed ID: 25812698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.